579 results about "Autoimmunity" patented technology

The present invention provides a therapeutic or prophylactic agent as a substitute for conventional steroids or immunosuppressive agents to treat or prevent systemic erythematosus, glomerulonephritis, lupus nephritis, idiopathic thrombocytopenic purpura or autoimmune anemia. The agent comprises a retinoic acid receptor agonist, specifically a retinoic acid receptor subtype alpha (RARalpha) agonist, including for example:(1) carboxylic acid compounds having condensed rings represented by the following formula: (wherein the rings L and M are condensed, are the same as or different from each other, and represent an aromatic hydrocarbon which may have a substituent group or a heterocycle which may have a substituent group; the rings A and B are independent of each other and represent an aromatic hydrocarbon ring or heterocycle which may have a substituent group; and D represents a carboxyl group which may have a protective group),(2) 4-{[(3,5-bistrimethylsilylphenyl)carbonyl]amino}benzoic acid, 4-{2-[5-(3-methoxymethyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-yl)pyrrolyl]}benzoic acid, etc.

The invention discloses an enzyme kinase drink. The enzyme kinase drink is prepared by the following steps: cleaning and crushing mandarin oranges, mulberry fruits, blueberries, apples, peaches, plums, apricots, pears, red pomelos, red jujubes, persimmons, figs, Chinese wolfberries, hawthorn, pineapples, bananas, pomegranates, sweet potatoes, lotus roots, fresh ginger, carrots, iron stick yams, fresh lentinus edodes, black beans, red beans and black rice, adding probiotics and fermenting for three times. The enzyme kinase drink has the advantages of high nutritional value, comprehensive probiotics required for a human body, easy absorption by the human body and capability of playing an important role in reactivating the autoimmunity of the human body.

The present invention relates generally to compositions and methods using mammalian, dsDNA (Double Stranded Deoxyribonucleic Acid) vaccination for the induction and maintenance of regulator suppressor T cells resulting in suppression of non infectious, and post infectious, inflammatory, allergic, auto-immune, vasculitic, certain degenerative vascular, and graft versus host diseases, with or without the use of IL-10, and with or without the use or TGFβ, with or without the use of anti-IL 6 receptor antibody, anti TNF antibody and or Plasmapheresis, IVIG, Corticosteroids, Methotrexate, Bromocriptine, and or vitamin D analogues.

The present invention provides a group of new stilbene derivatives and pharmacologically acceptable salts thereof, a method for preparing the compound, a pharmaceutical composition thereof and the compound as a therapeutic agent for immune diseases, inflammation and autoimmunity. Application in immune disease reagents.

The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

A method for the in vitro diagnosis of an autoimmune immune response in an individual by detection, in a biological fluid from said individual, of antibodies directed against the pentraxin 3 (PTX3) antigen, characterized in that the presence of antibodies directed against the PTX3 antigen (anti-PTX3 antibodies) are determined in a biological fluid from the individual, and kits for implementing the method.

The present invention relates to a method to stimulate reversal of a diabetic state in a patient; a method to prevent autoimmune destruction of new insulin-producing cells (pancreatic beta-cells) in a patient; a method to promote survival of the newly regenerated insulin-producing cells (pancreatic beta-cells); and an in vivo method for the induction of islet cell neogenesis and new islet formation and the prevention of autoimmune destruction of said new cells.

Disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, methods of improving vaccine efficacy, and methods of treating an infection. Also disclosed are methods of promoting tumor rejection, treating cancer, modulating autoimmunity and inhibiting allergen-induced hypersensitivity in subjects. The methods include contacting an NKT cell with a bacterial glycolipid complexed with a CD1 molecule to activate the NKT cell. The bacterial glycolipid may be derived from a member of the Class Alphaproteobacteria.

The invention describes novel nitrosated and/or nitrosylated rapamycin compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated rapamycin compound, and, optionally, at least one nitric oxide donor compound. The invention also provides novel compositions comprising at least one rapamycin compound and at least one nitric oxide donor compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating and/or preventing cardiovascular diseases, for the prevention of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating and/or preventing pathological conditions resulting from abnormal cell proliferation; transplantation rejections; autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering nitrosated and/or nitrosylated rapamycin compounds or rapamycin compounds in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions.

The present invention is directed to novel methods of producing ex vivo natural killer T (NKT) cells, and therapeutic uses thereof for treatment of certain conditions including cancer, autoimmunity, inflammatory disorders, allergic disorders, tissue transplant-related disorders, and infections.

The invention relates to a [1,2,4]triazol[1,5-a] pyridine compound as well as a preparation method and medical application thereof. Particularly, the invention relates to the compound shown in a general formula I, the preparation method of the compound, a medicinal composition containing the compound and application of the compound as a Janus kinase inhibitor. The compound and the medicinal composition containing the compound can be used for treating diseases related to the activity of Janus kinase, such as inflammation, autoimmune disease and cancer. The definitions of all substituent groupsin the general formula I are identical with those of the description. (The general formula is shown in the description).

The present invention relates to a compound of Formula I: or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.

The present invention provides an isolated antibody that binds a fibrin or fibrinogen γC domain. In various aspects, the antibody inhibits microglial adhesion to the fibrin or fibrinogen γC domain, inhibits Mac-1 binding to the fibrin or fibrinogen γC domain, and/or suppresses clinical symptoms of Experimental Autoimmune Encephalomyelitis (EAE). Various methods of using the antibodies, pharmaceutical compositions, kits, vectors, cells comprising the vectors, and antibody generating methods are provided.

The invention discloses a DNA flexagon nano structure-nanogold biosensor based on adapter modification and a preparing method and application of the DNA flexagon nano structure-nanogold biosensor. The biosensor comprises DNA flexagon and nanogold, the DNA flexagon comprises an adapter nucleotide sequence of a detected object, and the nanogold is nanogold modified by a DNA fragment complementary with the adapter nucleotide sequence. The method includes the following beneficial effects that the DNA flexagon has the accurate space addressability, and the complicated marking step is avoided after the nanogold is added; an adapter can be synthesized in batch with a chemical method, so that the cost is greatly reduced; the shortcoming that the autoimmunity of micromolecule matter is poor is overcome; the DNA flexagon nano structure-nanogold biosensor has the lower detection limit, and LOD reaches the nanogram stage; an atomic force microscope and electrophoresis are adopted for conducting representation, qualitative and quantitative analysis is carried out by using the characteristic that the nanogold is high in light in an atomic force microscope height map; and compared with a traditional survey method, the advantages of being easy and convenient, reliable, lower in requirement for experiment conditions and the like are achieved.